I know you are making an argumentum ad absurdum, but many hold exactly this position.
-
-
This tendency to want a pre-Kefauver Harris standard is not due to any rational consideration of the costs, risks, and benefits of lowering the standard for drug approval but almost entirely due to a hostility towards all regulation (other than regulation women's health).
-
Of course, this tendency to loosen FDA approval standards long predates the Trump administration, but the Trump administration accelerated it and put it on steroids. Scott Gottlieb was the "least worst" choice for FDA Commissioner at the time.
- Show replies
New conversation -
-
-
I get that, and I'm OK with it.
-
I, however, am not. Drugs are much more expensive now than they were in 1962 and the potential for disaster is much greater now than it was in 1962.
- Show replies
New conversation -
-
-
I favor more complete and careful uptake of real-world efficacy data, perhaps through the FDA or in a process/platform moderated by the agency.
-
"Real world" effectiveness data are very problematic for drugs for which there are significant placebo effects, such as pain medications and antidepressants. Also, there could be a lot of harm in the "real world" before such systems notice.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.